NO-flurbiprofen maintains duodenal blood flow, enhances mucus secretion contributing to lower mucosal injury

Abstract

This study investigates possible mechanisms behind the reduced gastrointestinal ulcerogenicity of nitric oxide (NO)-flurbiprofen compared with flurbiprofen. The duodenal mucosa of Inactin-anaesthetised rats was exteriorized for intravital microscopy. Blood flow was measured with laser-Doppler flowmetry (LDF), mucus thickness with micropipettes, ICAM-1 and P-selectin expression with dual-labeled antibody technique, and mucosal integrity by51Cr-EDTA permeability. Exposure of the duodenum to flurbiprofen (1.0 mg/ml) for 90 min significantly reduced LDF to 70 ± 4%, whereas NO-flurbiprofen (1.3 mg/ml) had no significant effect. Mucus accumulation after 60-min exposure was 75 ± 23 μm (control), −1 ± 17 μm (flurbiprofen), and 104 ± 35 μm (NO-flurbiprofen). Mucosal permeability to 51Cr-EDTA was unchanged in the control and NO-flurbiprofen groups but increased significantly from 1.0 ± 0.2 to 3.7 ± 0.7 μl · min−1 · g−1 after 90-min exposure to flurbiprofen. Expression of ICAM-1 was significantly increased after oral flurbiprofen but not by NO-flurbiprofen. Positive effects of NO-flurbiprofen compared with flurbiprofen on mucus formation, blood flow, and adhesion molecule expression likely contribute to the reduced mucosal injury observed with NO-flurbiprofen.